Gilead Sciences (GILD) Announces Results from Studies of Switching HIV-1 Patients to Descovy; Results Statistically non-Inferior

Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens

Descovy (FTC/TAF)-based Regimens Demonstrate Comparable Efficacy and Improved Renal and Bone Laboratory Parameters Compared to Truvada (FTC/TDF)-based Regimens

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced two-year (96-week) data from a Phase 3 study and 48-week data from two Phase 3b studies evaluating the safety and efficacy of switching virologically suppressed HIV-1 infected patients from regimens containing Truvada® (emtricitabine and tenofovir disoproxil fumarate... More